Network Oncology Inc.
(formerly Organach Beverage Acquisition Corp.)

Unaudited Consolidated Financial Statements

March 31, 2015

(Expressed in Canadian dollars)

NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS

Under National Instrument 51-102, Part 4, subsection 4.3 (3) (a), if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that an auditor has not reviewed the financial statements.

The accompanying unaudited interim financial statements of the Company have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these financial statements in accordance with standards established by the Canadian Institute of Chartered Accountants for a review of interim financial statements by an entity's auditor.

Network Oncology Inc. (formerly Organach Beverage Acquisition Corp.)
CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION
(Expressed in Canadian dollars)

	Note	March 31, 2015	December 31, 2014
		$	$
ASSETS			
Current Assets			
Cash		**1,469**	35,156
Sales tax receivable		**2,284**	-
Inventory		**5,689**	-
		9,442	35,156
Deposits on Acquisition Agreement	4	**-**	175,000
Intangible asset	5	**390,000**	-
		399,442	**210,156**
LIABILITIES			
Current Liabilities			
Accounts payable and accrued liabilities	4	**734,522**	45,880
Interest payable	6	**358**	-
Short term loan	6	**100,000**	-
Due to related party	10	**15,750**	-
		850,630	45,880
SHAREHOLDERS' EQUITY			
Share capital	7	**559,458**	100
Subscriptions received	7	**-**	250,000
Reserves	7	**30,642**	
Deficit		**(1,041,288)**	(85,824)
		451,188	164,276
		399,442	**210,156**

Nature of operations and going concern	1
Corporate restructuring and commitments	4

Approved and authorized for issuance by the Board of Directors on May 29, 2015:

Approved on Behalf of the Board of Directors:

/s/ William Thomas
Director

/s/ Manfred Nostitz
Director

The accompanying notes are an integral part of these consolidated financial statements

Network Oncology Inc. (formerly Organach Beverage Acquisition Corp.)
CONDENSED INTERIM STATEMENTS OF COMPREHENSIVE LOSS
(Expressed in Canadian dollars)

	Three Months Ended March 31	
	2015	2014
	$	$
Expenses		
Bank charges and fees	578	
Consulting	93,143	-
Development costs	812,699	
Interest expense	358	
Investor relations	2,253	
Office and miscellaneous	13,699	-
Professional fees	14,607	-
Regulatory fees	16,527	-
Travel	1,600	
Net loss and comprehensive loss	**(955,464)**	-
Basic and diluted loss per common share	**(0.01)**	(0.00)
Weighted average number of common shares outstanding	**60,357,070**	1

The accompanying notes are an integral part of these consolidated financial statements

Network Oncology Inc. (formerly Organach Beverage Acquisition Corp.)
CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY
(Expressed in Canadian dollars)

	Share Capital					
	Number of Shares	Amount	Subscription receivable	Reserves Warrants	Accumulated Deficit	Total
		$	$	$	$	$
Balance December 31, 2013	100	100	-	-	-	100
Stock split	150	-	-	-	-	-
Loss for the period	-	-	-	-	-	-
Balance, March 31, 2014	250	100	-	-	-	100
Balance December 31, 2014	**250**	**100**	**250,000**	**-**	(85,824)	**164,276**
Issuance on Plan of Arrangement	36,009,232	-	-	-	-	-
Issuance on acquisition closing	17,000,000	340,000	-	-	-	340,000
Private placement:						
Gross proceeds	12,500,000	250,000	(250,000)	-	-	-
Share issuance costs		(30,642)	-	30,642	-	-
Loss for the period	-	-	-	-	(955,464)	(955,464)
Balance, March 31, 2015	**65,509,482**	**559,458**		**30,642**	**(1,041,288)**	**(451,188)**

The accompanying notes are an integral part of these consolidated financial statements

Network Oncology Inc. (formerly Organach Beverage Acquisition Corp.)
CONDENSED INTERIM STATEMENTS OF CASH FLOW
(Expressed in Canadian dollars)

	Three Months Ended March 31	
	2015	2014
	$	$
Cash flow from operating activities		
Net loss	(955,464)	-
Change in non-cash working capital components:		
Sales tax receivable	(2,285)	-
Deposits and prepaid	125,000	-
Inventory	(5,689)	-
Accounts payable and accrued liabilities	688,643	-
Interest payable	358	-
Due to related party	15,750	-
Net cash used in operating activities	(133,687)	-
Financing activities		
Short term loan	100,000	100
Increase (decrease) in cash	(33,687)	100
Cash, beginning of year	35,156	-
Cash, ending of year	**1,469**	100

Cash paid for interest expense	-	-
Cash paid for income taxes	-	-

The accompanying notes are an integral part of these consolidated financial statements

1. NATURE OF OPERATIONS AND GOING CONCERN

Network Oncology Inc. (the "Company", formerly Organach Beverage Acquisition Corp.) was incorporated on September 19, 2013. The Company is a B.C. fully reporting company. The address of the registered office is Suite 500, 900 West Hastings Street, Vancouver, British Columbia, Canada V6C 1E5.

The Company was initially formed as a subsidiary of Web Watcher Systems Ltd. ("Web Watcher") for the purpose of developing the letter of intent with WULU Beverage Co. ("WULU") dated June 27, 2013 to distribute quality organic and fair trade coffees, glacier drinking water, and carbonated water manufactured by WULU. The Company entered into to a Plan of Arrangement (the "Plan of Arrangement") with Web Watcher Systems and WULU dated October 23, 2013. This Letter of Intent was cancelled by WULU on March 21, 2014 (see also Note 4).

On May 12, 2014, the Company entered into a Supply Agreement Sale and Assignment (the "Acquisition Agreement") with Resolute Oncology Limited ("ROL"), an Ireland company. The Company is now in the process of commencing operations as an emerging specialty pharmaceutical company working with ROL's core portfolio of oncology-targeted generic pharmaceuticals, which address a market comprised of up to 50% of new cancer patients in the European Union. The Company intends to focus on the acquisition and commercialization of proven, and thus low-risk, generic pharmaceutical oncology based products that provide a cost effective response to unmet needs in the market, specifically Germany and other major European countries, with possible expansion to the United States (see also Note 4).

On August 12, 2014, the Company changed its name to Network Oncology Inc.

These consolidated financial statements have been prepared on the basis of accounting principles applicable to a going concern which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business rather than through a process of forced liquidation. The Company's continuing operations, as intended, and its financial success may be dependent upon the extent to which it can successfully raise the capital to complete the Acquisition Agreement and subsequently carry out its business plan. If the Company is unable to fund its future plan, its business, financial condition or results of operations could be materially and adversely affected. The success of the Company depends on its ability to profitably penetrate its target market with its new products on a sustainable basis. The Company has never generated revenue, cash flows or profits from operations.

The Company's ability to launch its operations as intended is dependent on its ability to generate revenue and raise capital sufficient to cover its marketing and other costs. All of these factors raise significant doubt about the Company's ability to continue as a going concern. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should the Company be unable to continue in existence.

2. BASIS OF PRESENTATION

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board ("IASB").

2. BASIS OF PRESENTATION (continued)

These consolidated financial statements are presented in Canadian dollars, which is the Company's reporting and functional currency. The functional currency of the Company's wholly-owned subsidiary Emerald Oncology Limited is the EURO(€). These consolidated financial statements are prepared on a historical cost basis except for financial instruments classified as at fair value through profit or loss ("FVTPL") as described at Note 3 of the December 31, 2014 audited financial statements, which are stated at their fair value. In addition, these consolidated financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

Basis of consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary Emerald Oncology Limited which was incorporated on September 29, 2014 in the jurisdiction of Ireland. Inter-company balances and transactions, including unrealized income and expenses arising from inter-company transactions, are eliminated in preparing the consolidated financial statements.

3. FUTURE CHANGES IN ACCOUNTING POLICIES

<u>Future changes in accounting policies</u>

A number of new standards, and amendments to standards and interpretations, are not yet effective for the year ended at December 31, 2014, and have not been applied in preparing these financial statements. The following standards and interpretations have been issued by the IASB and the IFRIC effective for annual periods beginning on or after January 1, 2015:

IAS 32 - *Financial Instruments: Presentation*
In December 2011, the IASB issued an amendment to clarify the meaning of the offsetting criterion and the principle behind net settlement, including identifying when some gross settlement systems may be considered equivalent to net settlement. Earlier application is permitted when applied with corresponding amendment to IFRS 7.

IAS 36 – *Impairment of Assets*
In May 2013, the IASB, as a consequential amendment to IFRS 13 *Fair Value Measurement*, modified some of the disclosure requirements in IAS 36 regarding measurement of the recoverable amount of impaired assets. The amendments resulted from the IASB's decision in December 2010 to require additional disclosures about the measurement of impaired assets (or a group of assets) with a recoverable amount based on fair value less costs of disposal.

IFRIC 21 – *Levies*
IFRIC 21 provides guidance on when to recognize a liability for a levy imposed by a government, both for levies that are accounted for in accordance with IAS 37 *Provisions, Contingent Liabilities and Contingent Assets* and those where the timing and amount of the levy is certain.

The following standard will be effective for annual periods beginning on or after January 1, 2017:
IAS 1 – *Presentation of Financial Statements*
In December 2014, the IASB issued an amendment to address perceived impediments to preparers exercising their judgment in presenting their financial reports. The changes clarify that materiality considerations apply to all parts of the financial statements and the aggregation and disaggregation of line items within the financial statements.

3. SIGNIFICANT ACCOUNTING POLICIES (continued)

IFRS 15 - *Revenue from contracts with customers*
IFRS 15 deals with revenue recognition and establishes principles for reporting useful information to users of financial statements about the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. Revenue is recognized when a customer obtains control of a good or service and thus has the ability to direct the use and obtain the benefits from the good or service. The standard replaces IAS 18 'Revenue' and IAS 11 'Construction contracts' and related interpretations.

IAS 16 – *Property, Plant and Equipment* and IAS 38 – *Intangible Assets*
In May 2014, the IASB issued amendments to IAS 16 Property, Plant and Equipment and IAS 38 Intangible Assets. The amendments clarify that the use of revenue-based methods to calculate the depreciation of an asset is not appropriate because revenue generated by an activity that includes the use of an asset generally reflects factors other than the consumption of the economic benefits embodied in the asset. The amendments also clarify that revenue is generally presumed to be an inappropriate basis for measuring the consumption of the economic benefits embodied in an intangible asset. This presumption, however, can be rebutted in certain limited circumstances.

The following standard will be effective for annual period beginning on or after January 1, 2019:

IFRS 9 – *Financial Instruments*
IFRS 9 includes requirements for recognition and measurement, derecognition and hedge accounting. IFRS 9 was originally issued on November 2009, reissued in October 2010, and then amended in November 2013. The IASB is adding to the standard as it completes the various phases of its comprehensive project on financial instruments, and so it will eventually form a complete replacement for IAS 39 Financial Instruments: Recognition and Measurement.

In July 2014, the IASB published the final version of IFRS 9 bringing together the classification and measurement, impairment and hedge accounting phases of the IASB project to replace IAS 39. This version adds a new expected loss impairment model and limited amendments to classification and measurement of financial assets. IFRS 9 is effective for periods beginning on or after May 1, 2018.

The extent of the impact of adoption of these standards and interpretations on the consolidated financial statements of the Company has not been determined.

4. CORPORATE RESTRUCTURING AND COMMITMENTS

According to the Plan of Arrangement as described in Note 1, the Company is required to issue 14,403,698 common shares (pre-stock split) to shareholders of Web Watcher ("Distributed Shares"). The Plan of Arrangement was approved by Web Watcher's shareholders on December 19, 2013 and by the Supreme Court of British Columbia on January 7, 2014. Subsequent to the year end, the Company issued 36,009,245 common shares after the effect of the stock split on July 11, 2014. See also Notes 5(b) and 10(b).

On May 12, 2014, the Company entered into an Acquisition Agreement with ROL for an asset acquisition whereby certain assets were acquired in exchange for $50,000 in cash (paid in April 2014), issuance of 15,000,000 common shares, payment of 3% net sales royalty and continued fund raising as part of the private placement (see Note 10(a)). On July 31, 2014, the Acquisition Agreement was amended to change the closing date to the date that the shares of the Company are approved for trading on the Canadian Stock Exchange and increased the number of shares to be issued to 17,000,000 common shares (post-stock split) (issued in January 2015). In addition the Company had advanced $125,000 to ROL as of December 31, 2014. The assets to be acquired by the Company under the Acquisition Agreement comprise the following material agreements:

4. CORPORATE RESTRUCTURING AND COMMITMENTS (continued)

1. Agreement on Sale and Purchase of Dossier for Docetaxel between AqVida GmbH of Hamburg, Germany and ROL, dated June 6, 2013. Pursuant to the agreement, AqVida GmbH granted to ROL and its affiliates the non-exclusive right to use dossier and know-how associated with Docetaxel concentrate, to obtain marketing authorizations and to sell products in Germany, France, the United Kingdom, Spain, Italy, the Netherlands, Belgium, Austria, Switzerland, Sweden, Denmark, Finland, and Norway. The purchase price is EUR70,000 for marketing authorizations in Germany, and EUR10,000 for every other country, payable in the following installments:

   (i) EUR35,000 after signing the binding term sheet (signed and not paid by ROL);
   (ii) EUR35,000 after replying to a deficiency letter and restarting the procedure (not paid by ROL);
   (iii) EUR10,000 upon receipt of marketing authorizations in each further country in the territory.

   In addition, the Company is also responsible for all the fees charged by the Governmental or Regulatory Authorities related to obtaining the marketing authorizations.

2. Agreement on Sale and Purchase of Dossier for Paclitaxel, dated February 22, 2013, between AqVida GmbH of Hamburg, Germany and ROL and Resolute Oncology Inc. ("ROI"), the parent company of ROL, incorporated in Nevada, the United States of America. Pursuant to the agreement, Aqvida GmbH granted to ROL and ROI the non-exclusive right to use the dossier and know-how associated with Paclitaxel concentrate, to obtain marketing authorizations and to sell products in Germany, France, the United Kingdom, Spain, Republic of Ireland, Italy, the Netherlands, Belgium, Austria, Switzerland, Sweden, Denmark, Finland, and Norway. The purchase price is EUR70,000 for marketing authorizations in Germany, and EUR10,000 for every other country, payable in the following installments:

   (i) EUR35,000 after signing the binding term sheet (signed) (paid by ROL);
   (ii) EUR35,000 after transferring the German marketing authorization in the name of ROI (paid by ROL);
   (iii) EUR10,000 upon receipt of marketing authorizations in each further country in the territory.

   In addition, the Company is also responsible for all the fees charged by the Governmental or Regulatory Authorities related to obtaining the marketing authorizations.

3. Agreement on Sale and Purchase of Dossier for Oxaliplatin between AqVida GmbH of Hamburg, Germany and ROL and ROI, dated March 28, 2013. Pursuant to the agreement, Aqvida GmbH granted to ROL and ROI the non-exclusive right to use the dossier and know-how associated with Oxaliplatin concentrate, to obtain marketing authorizations and to sell products in Germany, France, the United Kingdom, Spain, Republic of Ireland, Italy, the Netherlands, Belgium, Austria, Switzerland, Sweden, Denmark, Finland, and Norway. The purchase price is EUR50,000 for the marketing authorization in Germany, and EUR 10,000 for every other country, payable in the following installments:

   (i) EUR50,000 upon transfer of the German marketing authorizations in the name of Resolute or its affiliates (paid by ROL);
   (ii) EUR10,000 upon receipt of a marketing authorization in each further country in the territory.

   In addition, the Company is also responsible for all the fees charged by the Governmental or Regulatory Authorities related to obtaining the marketing authorizations.

4. CORPORATE RESTRUCTURING AND COMMITMENTS (continued)

4. Principal Agreement between Neogen Developments N.V. ("Neogen") of Anderlecht, Belgium and ROL, dated March 20, 2013. Pursuant to the agreement, Neogen granted ROL a personal, non-exclusive, and non-transferable right to use registration documentation for zoledronic acid 4 mg/5 ml vial and zoledronic acid 4 mg/100 ml to obtain one marketing authorization in Spain, the United Kingdom, Germany, and Italy and two marketing authorizations in France, for the purpose of selling, marketing, and distributing the products in the territory. The initial term of this agreement is 5 years. Upon expiry of the initial term, the agreement will automatically extend for consecutive periods of 2 years.

   ROL has the right to convert the license to an exclusive license in Spain, the United Kingdom, France, and Germany within six months of signing the agreement by matching any offer made by a third party for a license in that country within seven days of being notified by Neogen or by paying an additional EUR39,000, whichever is higher. For Italy, ROL has the option of converting the license to a semi-exclusive license (two parties) within six months of signing the agreement by matching any offer made by a third party for a license in that country within seven days of being notified by Neogen or by paying an additional EUR39,000, whichever is higher.

   On February 11, 2015 the Principal Agreement between Neogen and ROL was amended such that that the rights on the registration documents will be limited to the 4 mg/5 ml product and to Germany only. All other rights will be transferred back to Neogen. In addition, the total amount to be paid for 4 mg/5 ml product would be to as follows:

   (i) EUR 145,000 in relation to this agreement covering milestones, service charges as well as fees paid to regulatory authorities;
   (ii) An amount of EUR 186,500 in relation to the purchase orders.

   The amended agreement indicated ROL will pay only EUR 150,000 by monthly installments of EUR 10,000 each month with the first payment due on February 15, 2015 (paid). Prior to December 31, 2014, ROL has paid EUR 50,000 to Neogen. In any event any payment is missed, Neogen shall be entitled to initiate proceedings for the overall debt of EUR 331,500 less the payments which have been made.

   On March 19, 2015 the Company signed a letter of guarantee for the repayment of the outstanding balance payable on this agreement by ROL. EUR 130,000 remains unpaid at March 31, 2015 and is included in accounts payable.

5. Three year Service Agreement between World Medical Care GmbH & Co ("WMC") KG of Hamburg, Germany and ROL, dated March 20, 2014. Pursuant to the agreement, WMC will exclusively sell and distribute ROL products.

   On August 15, 2014, ROL terminated the service agreement.

(Expressed in Canadian dollars)

5. INTANGIBLE ASSET

The intangible asset comprises the Acquisition Agreement assets described in Note 1 and Note 4.

	Acquisition Agreement Assets
COST	$
Balance, January 1, 2015	-
Additions	390,000
Balance, March 31, 2015	390,000

	Acquisition Agreement Assets
ACCUMULATED AMORTIZATION	$
Balance, January 1, 2015	-
Additions	-
Balance, March 31, 2015	-

	Acquisition Agreement Assets
Balance, January 1, 2015	$
Additions	-
Balance, March 31, 2015	-

6. SHORT TERM LOANS

During the period ended March 31, 2015, the Company received $100,000 short term and unsecured loan. The short term loans can be called at any time and bear an annual 8% simple interest rate.

7. SHARE CAPITAL

(a) Authorized: unlimited common shares without par value
(b) Issued and Outstanding:

Period Ended March 31, 2015

On January 8, 2015 the Company completed its private placement and issued 12,500,000 units at $0.02 per unit for proceeds of $250,000. Each unit comprised of one common share and one common share purchase warrant exercisable at $0.05 until January 8, 2016.

On January 8, 2015 the Company issued 36,009,232 common shares under the plan of arrangement between the Company and Web Watcher Systems Ltd. which was approved by the shareholders of Web Watcher Systems Ltd. on December 19, 2013 and the Supreme Court of British Columbia on January 7, 2014.

7. SHARE CAPITAL (continued)

On January 8, 2015, the Company issued 17,000,000 common shares in accordance with the Acquisition Agreement of which 2,500,000 common shares were issued to officers and directors of the Company.

Year Ended December 31, 2014

On July 11, 2014, the Company completed a stock split of its existing share capital on the basis of two and one-half new common shares (2.5) for every one (1) currently issued and outstanding common share, resulting in an aggregate of 250 common shares.

As at December 31, 2014, the Company had received $250,000 in private placement proceeds for 12,500,000 units at $0.02 per unit. Each unit comprised of one common share and one common share purchase warrant exercisable at $0.05 for a period of one year from the closing date. The shares and warrants were issued subsequent to the year end. See Note 10(a).

(c) Stock Options:

The Company has adopted an incentive stock option plan (the "Option Plan") which provides that the Board of Directors of the Company may from time to time, in its discretion, and in accordance with the applicable stock exchange's requirements, grant to directors, officers, employees and consultants to the Company, non-transferable options to purchase common shares. Pursuant to the Option Plan, the number of common shares reserved for issuance will not exceed 10% of the issued and outstanding common shares of the Company. Options granted under the Option Plan can have a maximum exercise term of 5 years from the date of grant. Vesting terms will be determined at the time of grant by the Board of Directors. As at March 31, 2015 and December 31, 2014, no options were granted or outstanding.

(c) Warrants:

As part of the January 8, 2015 private placement, the Company granted 12,500,000 share purchase warrants exercisable at $0.05 per share. These warrants expire on January 8, 2016.

8. CAPITAL DISCLOSURES

The Company's objectives when managing capital are to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders. The Company considers the items included in shareholders' equity as capital. The Company manages the capital structure and makes adjustments to it in response to changes in economic conditions and the risk characteristics of the underlying assets. The Company's primary objective with respect to its capital management is to ensure that it has sufficient cash resources to fund the operation of the Company. To secure the additional capital necessary to pursue these plans, the Company intends to raise additional funds through equity or debt financing. The Company is not subject to any capital requirements imposed by a regulator.

9. FINANCIAL INSTRUMENTS

Classification of financial instruments

	Ref.	**March 31, 2015**	December 31, 2014
		$	$
FVTPL financial asset	a	**3,753**	35,156
Other financial liabilities	b	**850,630**	45,880

a. Comprises cash and sales tax receivable
b. Comprises accounts payable, accrued liabilities, due to related parties, short term loans, and interest payable.

The fair value of the Company's financial assets and liabilities approximates the carrying amount.

Management of Industry and Financial Risk

The Company is engaged primarily in the sales and distribution of approved drugs and manages related industry risk issues directly. The Company may be at risk for regulatory issues and fluctuations in exchange rates.

The Company's financial instruments are exposed to certain financial risks, which include the following:

Credit risk
Credit risk is the risk of loss due to the counterparty's inability to meet its obligations. The Company's exposure to credit risk is on its cash and other receivables. Risk associated with cash is managed through the use of major banks which are high credit quality financial institutions as determined by rating agencies. Other receivables comprise refundable sales tax credits from the Canadian federal government.

Liquidity risk
Liquidity risk is the risk that the Company will encounter difficulties in meeting obligations when they become due. The Company ensures that there is sufficient capital in order to meet short-term operating requirements, after taking into account the Company's holdings of cash.

Foreign exchange risk
Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency.

Interest Rate Risk
Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to significant interest rate risk.

Capital management
The Company's policy is to maintain a strong capital base so as to maintain investor and creditor confidence and to sustain future development of the business. The capital structure of the Company consists of equity, net of cash and cash equivalents. There were no changes in the Company's approach to capital management during the year. The Company is not subject to any externally imposed capital requirements.

10. RELATED PARTY TRANSACTIONS

The Company incurred $15,750 (March 31, 2014 – $NIL) of consulting fees from the Chief Financial Officer and Director of the Company relating to consulting services provided. As at March 31, 2015, $15,750 (December 31, 2014 - $NIL) remains unpaid.